Singapore markets open in 5 hours 53 minutes

Valerio Therapeutics Société anonyme (C4X.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.1040-0.0100 (-8.77%)
As of 09:27AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 17.72M
Enterprise value 10.43M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)12.17
Price/book (mrq)0.76
Enterprise value/revenue 7.23
Enterprise value/EBITDA -0.53

Trading information

Stock price history

Beta (5Y monthly) 1.63
52-week change 3-58.99%
S&P500 52-week change 322.64%
52-week high 30.3320
52-week low 30.0840
50-day moving average 30.1122
200-day moving average 30.1752

Share statistics

Avg vol (3-month) 3251
Avg vol (10-day) 3N/A
Shares outstanding 5154.08M
Implied shares outstanding 6156.78M
Float 870.04M
% held by insiders 125.88%
% held by institutions 126.93%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,368.33%

Management effectiveness

Return on assets (ttm)-24.50%
Return on equity (ttm)-74.37%

Income statement

Revenue (ttm)1.44M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -19.68M
Net income avi to common (ttm)-19.73M
Diluted EPS (ttm)-0.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.83M
Total cash per share (mrq)0.11
Total debt (mrq)13.59M
Total debt/equity (mrq)58.64%
Current ratio (mrq)1.79
Book value per share (mrq)0.15

Cash flow statement

Operating cash flow (ttm)-17.12M
Levered free cash flow (ttm)-9.61M